russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2014-4-17-21russjcardiol-47Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРОЛЬ ДИГИДРОПИРИДИНОВЫХ АНТАГОНИСТОВ КАЛЬЦИЯ ПРИ ЛЕЧЕНИИ БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ И ОЖИРЕНИЕМ В СООТВЕТСТВИИ С СОВРЕМЕННЫМИ КЛИНИЧЕСКИМИ РЕКОМЕНДАЦИЯМИDIHYDROPYRIDINE CALCIUM ANTAGONISTS AND THE TREATMENT OF ARTERIAL HYPERTENSION AND OBESITY PATIENTS IN ACCORDANCE WITH THE MODERN CLINICAL GUIDELINESГиляревскийС. Р.GilyarevskyiS. R.

д.м.н., профессор кафедры клинической фармакологии и терапии

sgilarevsky@rambler.ruГолшмидМ. В.GoldschmidtM. V.

к.м.н., доцент кафедры клинической фармаколо­гии и терапии

КузьминаИ. М.KuzminaI. M.

к.м.н., ведущий научный сотрудник отделения неотложной кардиологии

Российская медицинская академия последипломного образованияРоссияRussian Medical Academy of Post-diploma EducationRussian FederationНИИ скорой помощи им. Н. В. Склифосовского, Москва, РоссияРоссияN.V. sklifosovskyi Research Institute of Emergency Medicine, Moscow, RussiaRussian Federation20142804201404113119Copyright © Гиляревский С.Р., Голшмид М.В., Кузьмина И.М., 20142014Гиляревский С.Р., Голшмид М.В., Кузьмина И.М.Gilyarevskyi S.R., Goldschmidt M.V., Kuzmina I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/47

В обзоре обсуждаются возможности использования универсальной комбини­рованной терапии дигидропиридиновым антагонистом кальция — лерканидипином для достижения целевых уровней артериального давления.

This review discusses the potential of a combination antihypertensive therapy with lercanidipine, a dihydropyridine calcium antagonist, for the achievement of target blood pressure levels.

артериальное давлениелерканидипинblood pressureж lercanidipineReferencesMancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European society of Hypertension (EsH) and of the European society of cardiology (ESC). Eur Heart J 2013; 34: 2159-219.Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European society of Hypertension (EsH) and of the European society of cardiology (ESC). Eur Heart J 2013; 34: 2159-219.James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens 2014; 32: 3-15.Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens 2014; 32: 3-15.Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.Messerli FH, Bangalore S. Diuretic-based regimens for obese patients? Lancet 2012; 381: 512-3.Messerli FH, Bangalore S. Diuretic-based regimens for obese patients? Lancet 2012; 381: 512-3.Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-32.Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-32.McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006; 144: 517-24.McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006; 144: 517-24.Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863-70.Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863-70.Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2012; 381: 537-45.Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2012; 381: 537-45.Astashkin E. I., Glezer M. G. Lipotoxic effects in heart in patient with obesity. Arterial hypertension 2009; 15: 335-41. Russian (Асташкин Е. И., Глезер М. Г. Липотоксические эффекты в сердце, наблюдаемые при ожирении. Артериальная гипертензия 2009; 15: 335-41).Astashkin E. I., Glezer M. G. Lipotoxic effects in heart in patient with obesity. Arterial hypertension 2009; 15: 335-41. Russian (Асташкин Е. И., Глезер М. Г. Липотоксические эффекты в сердце, наблюдаемые при ожирении. Артериальная гипертензия 2009; 15: 335-41).Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117: 2706-15.Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117: 2706-15.Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7.Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7.Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.National Institute for Health and Clinical Excellence. Clinical management of primary hypertension in adults. August, 2011. http://www.nice.org.uk/nicemedia/ live/13561/56008/56008.pdf (accessed Nov 20, 2012).National Institute for Health and Clinical Excellence. Clinical management of primary hypertension in adults. August, 2011. http://www.nice.org.uk/nicemedia/ live/13561/56008/56008.pdf (accessed Nov 20, 2012).Sener D, Halil M, Yavuz BB, et al. Anasarca edema with amlodipine treatment. Ann Pharmacother 2005; 39: 761-3.Sener D, Halil M, Yavuz BB, et al. Anasarca edema with amlodipine treatment. Ann Pharmacother 2005; 39: 761-3.Otero M. Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag 2007; 3: 255-63.Otero M. Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag 2007; 3: 255-63.Barrios V, Escobar C, de la Figuera M, et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62: 723-8.Barrios V, Escobar C, de la Figuera M, et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62: 723-8.Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006; 60: 1364-70.Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006; 60: 1364-70.Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanid- ipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens 2003; 5: 249-53.Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanid- ipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens 2003; 5: 249-53.Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27: 73-80.Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27: 73-80.

The authors declare that there are no conflicts of interest present.